OMER Projected Dividend Yield
Omeros Corp ( NASDAQ : OMER )Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The primary drug candidate in its pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. 20 YEAR PERFORMANCE RESULTS |
OMER Dividend History Detail OMER Dividend News OMER Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |